A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Inclusion Criteria:
1. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:
Exclusion Criteria:
Daw Park SA, Australia
Mississuaga, Ontario, Canada
North York, Ontario, Canada
Naka-gun, Japan
Sochy, Russia
Kinikli/Denizli, Turkey (Türkiye)
Soke/Aydin, Turkey (Türkiye)
Yenisehir/Izmir, Turkey (Türkiye)